Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

Abstract Background Previous studies showed that type 2 short bowel syndrome (SBS) rats were accompanied by severe intestinal bacterial dysbiosis. Limited data are available for fungal Moreover, no effective therapeutic drugs these microbiota The aims of our study to investigate the potential glucagon-like peptide (GLP-2) dysbiosis in SBS rats. Methods 8-week-old male SD which underwent 80% small resection, ileocecum partial colon resection and jejunocolostomy, treated with saline (SBS group, n = 5) or GLP-2 (GLP2.SBS 5). Sham group transection re-anastomosis given a placebo (Sham 16S rRNA ITS sequencing applied evaluate colonic composition at 22 days after surgery, respectively. Results relative abundance Actinobacteria, Firmicutes proinflammatory Proteobacteria increased significantly rats, while Bacteroidetes, Verrucomicrobia Tenericutes decreased remarkably. treatment Proteus Clostridium diversity fungi was some abnormally resident (e.g., Penicillium) decreased. Debaryomyces Meyerozyma, Penicillium. partially restored bacteria-fungi interkingdom interaction network Conclusion Our confirms ameliorated